Separation of Sc/Sc Nuclear Isomers Based on After-Effects.

Sc presents a particular interest for application in nuclear medicine for positron emission tomography (PET) due to its favorable nuclear decay properties ( = 3.97 h, = 1.47 MeV, branching ratio 94.

Production and radiochemistry of antimony-120m: Efforts toward Auger electron therapy with Sb.

Targeted Meitner-Auger Therapy (TMAT) has potential for personalized treatment thanks to its subcellular dosimetric selectivity, which is distinct from the dosimetry of β and α particle emission based Targeted Radionuclide Therapy (TRT). To date, most clinical and preclinical TMAT studies have used commercially available radionuclides. These studies showed promising results despite using radionuclides with theoretically suboptimal photon to electron ratios, decay kinetics, and electron emission spectra.

An alternative radiochemical separation strategy for isolation of Ac and Ra isotopes from high energy proton irradiated thorium targets for further application in Targeted Alpha Therapy (TAT).

Targeted Alpha Therapy (TAT) has shown very high potential for the treatment of cancers that were not responsive to other therapy options (e.g., β therapy and chemotherapy).

Improved separation scheme for Sc produced by irradiation of Ca targets with 12.8 MeV protons.

Introduction: Sc is of great interest as a positron emission tomography (PET) radionuclide due to its suitable nuclear characteristics: E = 1.47 MeV, branching ratio 94.3% and convenient half-life of 3.

Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations.

Targeted Auger Therapy represents great potential for the therapy of diseases which require a high degree of selectivity on the cellular level (e.g. for therapy of metastatic cancers).